Search

CN-122005763-A - Composition for preventing or treating radioactive skin injury and application thereof

CN122005763ACN 122005763 ACN122005763 ACN 122005763ACN-122005763-A

Abstract

The application provides a composition for preventing or treating radioactive skin injury and application thereof, the composition comprises (1) recombinant type III collagen, (2) at least one hyaluronic acid or salt thereof with the molecular weight of 1000k-2500k Da, (3) at least one hyaluronic acid or salt thereof with the molecular weight of 200k-500k Da, and (4) at least one hyaluronic acid or salt thereof with the molecular weight of 30k-100kDa, wherein the component (a), the component (b) and the component (c) form a network structure, so that excellent external environment can be provided for the collagen, and the proliferation and migration of cells can be promoted by the recombinant collagen, and the two components are mutually cooperated.

Inventors

  • TIAN LILI
  • MEN FUMIN
  • CHEN WEIXIA
  • LI XIA
  • ZHU JIAOJIAO
  • LI YIHENG

Assignees

  • 华熙生物科技(海南)有限公司
  • 华熙生物科技股份有限公司

Dates

Publication Date
20260512
Application Date
20241111

Claims (9)

  1. 1. A composition for preventing or treating radiation skin damage comprising: (1) Recombinant type III collagen; (2) At least one hyaluronic acid or salt thereof having a molecular weight of 1000k-2500k Da; (3) At least one hyaluronic acid or salt thereof having a molecular weight of 200k-500k Da; (4) And (c) at least one hyaluronic acid or salt thereof with a molecular weight of 30-100 k Da.
  2. 2. The composition of claim 1, wherein, The mass ratio of the component (a), the component (b) and the component (c) is 0.4-3:0.4-3:0.4-3, preferably 0.3-1.5:0.8-2.5:0.3-2.
  3. 3. The composition according to claim 1 or 2, wherein the mass ratio of the recombinant type III collagen to the sum of the component (a), the component (b) and the component (c) is 1 (0.08-12).
  4. 4. A skin care formulation comprising the composition of any one of claims 1-3.
  5. 5. The skin care formulation according to claim 4, wherein the recombinant type III collagen is 0.02 to 1.0% by mass of the skin care formulation, and the sum of the component (a), the component (b) and the component (c) is 0.02 to 1.0%.
  6. 6. The skin care formulation according to claim 4 or 5, wherein the skin care formulation further comprises an adjuvant and/or an active ingredient.
  7. 7. Use of recombinant type III collagen and hyaluronic acid or a salt thereof for the preparation of a product for the prevention or treatment of radiation-induced skin lesions, wherein the hyaluronic acid or salt thereof comprises component (a) of at least one hyaluronic acid or salt thereof having a molecular weight of 1000k-2500k Da, component (b) of at least one hyaluronic acid or salt thereof having a molecular weight of 200k-500k Da, and component (c) of at least one hyaluronic acid or salt thereof having a molecular weight of 30k-100 kDa.
  8. 8. Use according to claim 7, wherein the mass ratio of component (a), component (b) and component (c) is 0.4-3:0.4-3:0.4-3, preferably 0.3-1.5:0.8-2.5:0.3-2.
  9. 9. The use according to claim 7 or 8, wherein the mass ratio of the recombinant type III collagen to the sum of the components (a), (b) and (c) is 1 (0.08-12).

Description

Composition for preventing or treating radioactive skin injury and application thereof Technical Field The application relates to the technical field of biological medicines, in particular to a composition for preventing or treating radioactive skin injury and application thereof. Background Radiation skin injury is a common complication of patients during radiation therapy, and radiation therapy-induced skin inflammation often occurs within 1-4 weeks of radiation therapy. The acute radiodermatitis is divided into 4 grades, namely, follicular dark red stain, alopecia, dry desquamation and perspiration reduction, namely, tender or bright red stain, flaky wet desquamation and moderate edema, namely, fusion wet desquamation and concave edema except skin folds, namely, necrosis, ulcer and hemorrhage, namely, grade-IV. At present, the potential occurrence mechanism of radioactive skin injury is largely unknown, a gold standard for treatment is not established after radiation injury, and the known occurrence mechanism of radioactive skin injury can be roughly divided into 3 paths, namely oxidative stress injury caused by the great increase of active oxygen, inflammation caused by the transcriptional activation of cytokines and immune response caused by bone marrow-derived cells. The most main means for clinically preventing and treating radioactive skin injury is mainly western medicines such as vitamins, corticosteroids, medical radioprotectors, bikini and the like, and the clinical application has limitation due to high price or poor curative effect of the medicines. The literature 'application research of collagen in radioactive skin injury prevention and treatment' (Mo Zhiwen et al, DOI:10.3969/j. Issn. 1002-7386.2012.11.013) shows that collagen can delay the occurrence time of radioactive skin injury, shorten the time for starting recovery of skin injury, and further infer that collagen has the effect of preventing radioactive skin injury. However, this document does not make an intensive study on the effect of collagen on the radioactive skin damage, and does not clearly understand the mechanism of the effect of collagen on the radioactive skin damage, and the effect of a single collagen on repairing the radioactive skin damage is limited, and how to further enhance the effect of collagen on repairing the radioactive skin damage is not further studied. Chinese patent application CN114470314A discloses a recombinant humanized collagen gel dressing, which comprises 0.001% -0.05% of recombinant humanized collagen, 0.005% -0.02% of fibronectin, 0.5% -2% of sodium hyaluronate, 0.1% -0.8% of heparan sulfate, 1% -10% of sugar alcohol compound, 0.5% -3% of 1, 2-pentanediol, 3% -8% of polydatin and the balance of water. The gel dressing can provide moist healing environment for wounds, promote cell growth at the wounds, and can be used for repairing non-chronic wounds. However, the radioactive skin damage is not an ordinary wound surface, and whether the restoration effect of the radioactive skin damage can be exerted after the active ingredients such as collagen, hyaluronic acid and the like are combined is not yet studied and reported at present. Therefore, how to effectively prevent and treat the radioactive skin injury is a technical problem to be solved at present. Disclosure of Invention In view of the technical problems existing in the prior art, the present application provides a composition for preventing or treating radioactive skin damage, which can prevent or treat radioactive skin damage by mixing a composition of recombinant type III collagen and hyaluronic acid or a salt thereof. The specific technical scheme of the application is as follows: a composition for preventing or treating radiation skin damage comprising: (1) Recombinant type III collagen; (2) At least one hyaluronic acid or salt thereof having a molecular weight of 1000k-2500k Da; (3) At least one hyaluronic acid or salt thereof having a molecular weight of 200k-500k Da; (4) And (c) at least one hyaluronic acid or salt thereof with a molecular weight of 30-100 k Da. Wherein, the The mass ratio of the component (a), the component (b) and the component (c) is 0.4-3:0.4-3:0.4-3, preferably 0.3-1.5:0.8-2.5:0.3-2, and most preferably 0.5-1:1-2:0.5-1.5. Further, the mass ratio of the recombinant type III collagen to the sum of the component (a), the component (b) and the component (c) is 1 (0.08-12), preferably 1 (0.1-10). The application also provides a skin care formulation comprising the above composition. Further, the recombinant type III collagen is 0.02 to 1.0% by mass of the skin care preparation, and the sum of the component (a), the component (b) and the component (c) is 0.02 to 1.0%. Further, the skin care formulation further comprises adjuvants and/or active ingredients. The application also provides the use of recombinant type III collagen and hyaluronic acid or a salt thereof in the manufacture of a product for the prevention or tre